lenalidomide has been researched along with Teratogenesis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bassermann, F; Eichner, R; Einsele, H; Fernández-Sáiz, V; Garz, AK; Germing, U; Götze, KS; Haass, C; Heider, M; Jacobs, L; Keller, U; Knop, S; Knorn, AM; Kuster, B; Langer, C; Lemeer, S; Peschel, C; Platzbecker, U; Rudelius, M; Schmid, B; Slawska, J; Targosz, BS; van Bebber, F | 1 |
1 other study(ies) available for lenalidomide and Teratogenesis
Article | Year |
---|---|
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Oncogene Proteins; Peptide Hydrolases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Teratogenesis; Thalidomide; Ubiquitin-Protein Ligases | 2016 |